托法替布在类风湿关节炎、银屑病及银屑病关节炎开发项目及真实世界数据中报告的血栓栓塞事件发生率
该研究基于托法替布在类风湿关节炎(RA)、银屑病(PsO)和银屑病关节炎(PsA)开发项目中的事后分析及真实世界数据,计算深静脉血栓(DVT)、肺栓塞(PE)、静脉血栓栓塞(VTE)和动脉血栓栓塞(ATE)的发生率。结果显示,在托法替布5 mg和10 mg每日两次剂量间血栓栓塞事件发生率相似,且通常与观察性数据及其他治疗已发表发生率一致;基线心血管或VTE风险因素患者发生率较高。
要点
- 托法替布5 mg和10 mg每日两次的DVT、PE、ATE发生率相似。
- 基线心血管或VTE风险因素患者血栓栓塞事件发生率较高。
- 开发项目发生率与Corrona登记等观察性数据大体一致。
核心结论
- 托法替布在RA、PsO和PsA项目中DVT、PE和ATE发生率在5 mg和10 mg每日两次剂量间相似,且与观察性数据及其他治疗已发表发生率基本一致。
- 基线心血管或VTE风险因素患者血栓栓塞事件发生率升高,与A3921133研究 ad hoc 安全性分析数据大体一致,但该研究中10 mg每日两次组PE发生率高于RA项目中具有基线心血管风险因素且接受10 mg每日两次治疗的患者。
研究设计与样本
- 事后分析,使用托法替布RA(排除A3921133研究)、PsO和PsA开发项目的独立数据,共纳入12 410例接受托法替布治疗的患者(RA:n=7964;PsO:n=3663;PsA:n=783)。
- 计算DVT、PE、VTE和ATE的发生率(每100患者年暴露的事件患者数),并按基线心血管或VTE风险因素分层。
- 分析美国Corrona登记(含心血管风险因素分层)、IBM MarketScan研究数据库和美国FDA不良事件报告系统(FAERS)数据库的观察性数据。
主要发现
- 在全部托法替布队列中,RA患者平均5 mg和10 mg每日两次治疗的DVT发生率分别为0.17(95%CI 0.09-0.27)和0.15(95%CI 0.09-0.22)。
- RA患者PE发生率分别为0.12(95%CI 0.06-0.22)和0.13(95%CI 0.08-0.21);ATE发生率分别为0.32(95%CI 0.22-0.46)和0.38(95%CI 0.28-0.49)。
- PsO患者DVT发生率分别为0.06(95%CI 0.00-0.36)和0.06(95%CI 0.02-0.15);PE分别为0.13(95%CI 0.02-0.47)和0.09(95%CI 0.04-0.19);ATE分别为0.52(95%CI 0.22-1.02)和0.22(95%CI 0.13-0.35)。
- PsA患者DVT发生率分别为0.00(95%CI 0.00-0.28)和0.13(95%CI 0.00-0.70);PE分别为0.08(95%CI 0.00-0.43)和0.00(95%CI 0.00-0.46);ATE分别为0.31(95%CI 0.08-0.79)和0.38(95%CI 0.08-1.11)。
- FAERS数据库中未发现托法替布与DVT、PE或ATE不成比例报告的信号。
关键数值与推荐
- DVT、PE、VTE和ATE的发生率以每100患者年暴露的事件患者数表示,并报告95%CI。
- 发生率按基线定义的心血管或VTE风险因素进行分层分析。
- FAERS数据库分析未发现托法替布与DVT、PE或ATE不成比例报告的信号。
临床怎么用
- 临床使用托法替布时应评估患者基线心血管和VTE风险因素,风险因素患者血栓栓塞事件发生率较高。
- 托法替布5 mg和10 mg每日两次的血栓栓塞事件发生率相似,但A3921133研究中10 mg每日两次组PE发生率较高,需结合患者情况个体化决策。
- 开发项目发生率与真实世界观察性数据基本一致,可为临床风险沟通提供参考。
局限性
- 事后分析设计可能引入偏倚。
- 观察性数据来自特定数据库,可能存在报告不完整或混杂。
- A3921133研究数据另行报告,未完全纳入本分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged ≥50 years and with ≥1 cardiovascular risk factor identified a higher frequency of pulmonary embolism (PE) and all-cause mortality for patients receiving tofacitinib 10 mg twice daily versus those receiving tumour necrosis factor inhibitors and resulted in identification of a safety signal for tofacitinib. Here, we report the incidence of deep vein thrombosis (DVT), PE, venous thromboembolism (VTE; DVT or PE) and arterial thromboembolism (ATE) from the tofacitinib RA (excluding Study A3921133), PsA and PsO development programmes and observational studies. Data from an ad hoc safety analysis of Study A3921133 are reported separately within. METHODS: This post-hoc analysis used data from separate tofacitinib RA, PsO and PsA programmes. Incidence rates (IRs; patients with events per 100 patient-years' exposure) were calculated for DVT, PE, VTE and ATE, including for populations stratified by defined baseline cardiovascular or VTE risk factors. Observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research database and the US FDA Adverse Event Reporting System (FAERS) database were analysed. RESULTS: 12 410 tofacitinib-treated patients from the development programmes (RA: n=7964; PsO: n=3663; PsA: n=783) were included. IRs (95% CI) of thromboembolic events among the all tofacitinib cohorts' average tofacitinib 5 mg and 10 mg twice daily treated patients for RA, respectively, were: DVT (0.17 (0.09-0.27) and 0.15 (0.09-0.22)); PE (0.12 (0.06-0.22) and 0.13 (0.08-0.21)); ATE (0.32 (0.22-0.46) and 0.38 (0.28-0.49)). Among PsO patients, IRs were: DVT (0.06 (0.00-0.36) and 0.06 (0.02-0.15)); PE (0.13 (0.02-0.47) and 0.09 (0.04-0.19)); ATE (0.52 (0.22-1.02) and 0.22 (0.13-0.35)). Among PsA patients, IRs were: DVT (0.00 (0.00-0.28) and 0.13 (0.00-0.70)); PE (0.08 (0.00-0.43) and 0.00 (0.00-0.46)); ATE (0.31 (0.08-0.79) and 0.38 (0.08-1.11)). IRs were similar between tofacitinib doses and generally higher in patients with baseline cardiovascular or VTE risk factors. IRs from the overall Corrona populations and in Corrona RA patients (including tofacitinib-naïve/biologic disease-modifying antirheumatic drug-treated and tofacitinib-treated) with baseline cardiovascular risk factors were similar to IRs observed among the corresponding patients in the tofacitinib development programme. No signals of disproportionate reporting of DVT, PE or ATE with tofacitinib were identified in the FAERS database. CONCLUSIONS: DVT, PE and ATE IRs in the tofacitinib RA, PsO and PsA programmes were similar across tofacitinib doses, and generally consistent with observational data and published IRs of other treatments. As expected, IRs of thromboembolic events were elevated in patients with versus without baseline cardiovascular or VTE risk factors, and were broadly consistent with those observed in the Study A3921133 ad hoc safety analysis data, although the IR (95% CI) for PE was greater in patients treated with tofacitinib 10 mg twice daily in Study A3921133 (0.54 (0.32-0.87)), versus patients with baseline cardiovascular risk factors treated with tofacitinib 10 mg twice daily in the RA programme (0.24 (0.13-0.41)).
引用
- Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020. PMID: 32759265. doi:10.1136/annrheumdis-2019-216761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。